BiotechTube

Piflufolastat F 18 Intravenous Solution [PYLARIFY]

ApprovedActive
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Prostate Cancer

Conditions

Prostate Cancer

Trial Timeline

Feb 8, 2024 → Sep 1, 2026

NCT ID
NCT06074510

About Piflufolastat F 18 Intravenous Solution [PYLARIFY]

Piflufolastat F 18 Intravenous Solution [PYLARIFY] is a approved stage product being developed by Lantheus Holdings for Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06074510. Target conditions include Prostate Cancer.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06074510ApprovedActive

Competing Products

20 competing products in Prostate Cancer

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
36
PemetrexedEli LillyPhase 2
52
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
77
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
Abemaciclib + Placebo + Abiraterone acetate + PrednisoneEli LillyPhase 2/3
65
eFT508eFFECTOR TherapeuticsPhase 2
44
EnhertuDaiichi SankyoPhase 2
52
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
PLX3397Daiichi SankyoPhase 2
52
Valemetostat + DarolutamideDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
33
degarelix + GoserelinAstellas PharmaPhase 3
77
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
23
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
52
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetateAstellas PharmaPhase 2
52

Other Products from Lantheus Holdings

3D HI and SHI of UCAApproved
82
Definity® Vial for (Perflutren Lipid Microsphere) Injectable SuspensionApproved
82
DefinityApproved
82
Technetium Tc99m SestamibiApproved
82
Perflutren Lipid Microsphere Injectable SuspensionApproved
82